Sugi Predict

Sugi Predict / Compounds / SCHEMBL933075

SCHEMBL933075

SCHEMBL933075

C=CCOCC(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ TSHR P16473 1/20 0.34
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ HDAC8 Q9BY41 1/20 0.33
▸ HDAC6 Q9UBN7 1/20 0.33
▸ MEN1 O00255 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ CYP2D6 P10635 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21069752 0.91 TDP1 (0.46) TDP1SMN1; SMN2L3MBTL1TSHRHDAC3
SCHEMBL18517724 0.83 TDP1 (0.39) TDP1SMN1; SMN2TSHRMEN1POLB
SCHEMBL2608192 0.81 L3MBTL1 (0.40) TDP1SMN1; SMN2L3MBTL1TSHRHDAC3
SCHEMBL6688426 0.80 DGAT1 (0.37) TDP1L3MBTL1HDAC3HDAC1HDAC2
SCHEMBL351309 0.79 L3MBTL1 (0.34) TDP1SMN1; SMN2L3MBTL1
SCHEMBL23728627 0.78 L3MBTL1 (0.38) TDP1SMN1; SMN2L3MBTL1TSHRHDAC3
SCHEMBL19595540 0.78 L3MBTL1 (0.38) TDP1SMN1; SMN2L3MBTL1TSHRHDAC3
SCHEMBL12092190 0.78 L3MBTL1 (0.38) TDP1SMN1; SMN2L3MBTL1TSHRHDAC3
SCHEMBL5211003 0.77 PTGS1 (0.34) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL5210998 0.77 PTGS1 (0.34) HDAC3HDAC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615849-A1 CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS Boehringer Ingelheim International GmbH (DE) 2025-09-17 — — EP disclosed
EP-4615578-A1 CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS Boehringer Ingelheim International GmbH (DE) 2025-09-17 — — EP disclosed
CN-120202206-A Cyclic benzimidazole derivatives as cGAS inhibitors 勃林格殷格翰国际有限公司 2025-06-24 — — CN disclosed
WO-2025007853-A1 2-INDOLINONE COMPOUND SERVING AS VEGFR AND PKA DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 远森制药（杭州）有限公司 2025-01-09 — — WO disclosed
US-20240208997-A1 CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-06-27 — — US disclosed
US-20240189315-A1 Cyclic Pyridine Derivatives as cGAS Inhibitors BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2024-06-13 — — US disclosed
WO-2024099907-A1 CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-16 — — WO disclosed
WO-2024099908-A1 CYCLIC PYRIDINE DERIVATIVES AS CGAS INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-16 — — WO disclosed
WO-2017025565-A1 2-AMINO-7A-PHENYL-3,4,4A,5,7,7A-HEXAHYDROFURO[3,4-B]PYRIDINES AS BACE1 INHIBITORS H. LUNDBECK A/S (DK) 2017-02-16 — — WO disclosed
EP-2451793-B1 BACE INHIBITORS LILLY CO ELI (US) 2016-11-02 — — EP disclosed
US-8278441-B2 BACE inhibitors ELI LILLY AND COMPANY (US) 2012-10-02 — — US disclosed
US-8278441-B2 BACE inhibitors ELI LILLY AND COMPANY (US) 2012-10-02 — — US disclosed
EP-2451793-A1 BACE INHIBITORS Eli Lilly and Company (US) 2012-05-16 — — EP disclosed
US-20110009395-A1 BACE INHIBITORS ELI LILLY AND COMPANY (US) 2011-01-13 — — US disclosed
US-20110009395-A1 BACE INHIBITORS ELI LILLY AND COMPANY (US) 2011-01-13 — — US disclosed
US-20110009395-A1 BACE INHIBITORS ELI LILLY AND COMPANY (US) 2011-01-13 — — US disclosed
WO-2011005738-A1 BACE INHIBITORS ELI LILLY AND COMPANY (US) 2011-01-13 — — WO disclosed
US-6376688-B1 Modified polyunsaturated fatty acids PEPTIDE TECHNOLOGY LIMITED (AU) 2002-04-23 — — US disclosed
EP-0869941-B1 MODIFIED POLYUNSATURATED FATTY ACIDS PEPTECH LTD (AU) 2001-12-12 — — EP disclosed
US-6262119-B1 ADMINISTERING POLYUNSATURATED FATTY ACID CONTAINING 18-25 CARBONS, 1-6 DOUBLE BONDS AND HAS ONE OR TWO SUBSTITUTIONS FOR THERAPY OF T-CELL MEDIATED DISEASES SUCH AS DIABETES, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, HERPES SIMPLEX ETC. PEPTIDE TECHNOLOGY LIMITED (AU) 2001-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208997-A1 CYCLIC BENZIMIDAZOLE DERIVATIVES AS CGAS INHIBITORS CGAS, STING1, IFNAR1 TDP1 57/4885SMN1; SMN2 3195/4885L3MBTL1 1066/4885
US-20110009395-A1 BACE INHIBITORS BACE1, BACE2, APP TDP1 279/4885SMN1; SMN2 961/4885L3MBTL1 3403/4885
US-20240189315-A1 Cyclic Pyridine Derivatives as cGAS Inhibitors CGAS, STING1, IRF3 TDP1 19/4885SMN1; SMN2 3762/4885L3MBTL1 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.